Evidence map›Paper›PMID 23599313›Full record

ArticleThe Journal of infectious diseases2013

Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

Anna-Barbara Moscicki, Yifei Ma, Sepideh Farhat, Teresa M Darragh, Michael Pawlita, Denise A Galloway, Stephen Shiboski

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anna-Barbara MoscickiDepartment of Pediatrics, University of California,San Francisco, CA, USA. moscickia@peds.ucsf.edu
Yifei Ma
Sepideh Farhat
Teresa M Darragh
Michael Pawlita
Denise A Galloway
Stephen Shiboski

Funding

ZIDOVUDINE &LAMIVUDINE &NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFM01RR001271 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KESSLER, DAVID A · 1985 to 2006
$22.7M
Natural History of HPV Infection to NeoplasiaR37CA051323 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MOSCICKI, ANNA-BARBARA · 2005 to 2014
$15.4M
NCI NIH HHS R37 CA051323NCRR NIH HHS 5 M01 RR-01271NCRR NIH HHS M01 RR001271
6 · The paper itself

Abstract

backgroundThe purpose of this study was to examine the rate of and risks for cervical human papillomavirus type 16 (HPV16) redetection in women with documented or suspected HPV16 infection.

methodsA convenience sample of women aged 13-21 years were seen at 4-month intervals for HPV DNA testing and cytology. Serum samples were obtained at baseline and annually.

resultsA total of 1543 women entered the study. Of the 295 women with detection of HPV16 DNA and subsequent clearance, 18.1% had HPV16 redetected by 8.5 years (88% cleared this second detection by 3 years). Of the 247 women who had antibodies to HPV16 and were HPV16 DNA negative at baseline, 15.3% had HPV16 redetected by year 5. Risks for redetection included douching, current use of medroxyprogesterone, reporting >1 sex partner or having a new sex partner, and having a sexually transmitted infection. Development of cervical intraepithelial neoplasia 2/3 was rare in women with redetection, except for those with prevalent HPV16 infection.

conclusionsReappearance of HPV16 DNA was observed in 18% of women. Most are associated with sexual exposure and appear benign. Interpretation of the studies is more complex in women with prevalent infections as it appears that this small subset reflects women with persistence already present at entry.

Indexed as

AdolescentAntibodies, ViralCervix UteriDNA, ViralFemaleHuman papillomavirus 16HumansLongitudinal StudiesPapillomavirus InfectionsRecurrenceRisk FactorsYoung AdultAntibodies, ViralDNA, Viralreactivationredetection of HPV16risk for acquisitionrisk for clearance

Identifiers

PMID23599313
PMCPMC3699002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.